Indian CRO, GVK Biosciences Joins ResearchPoint Global

Goldman Sachs said: “India presents an attractive region for clinical trials given a population of over one billion, a large number of English-speaking patients, and a well developed information technology industry.”

The move also provides RPG with an opportunity to expand its presence in India. It also benefits the firm with running clinical trials, a large population, qualified medical personnel, and well-established regulations. GVK Biosciences complements RPG’s current presence in the Americas, Europe and Africa.

Matt Walker, executive vice president of marketing and business development with ResearchPoint, said: “RPG is strategically expanding our global footprint with qualified, like-minded CROs who have extensive drug development experience across a broad range of therapeutic areas. GVK Biosciences has built an exceptional reputation as a full-service clinical service provider in India and we look forward to leveraging their deep local knowledge for the benefit of our clients.”

Paul Braconnier, governing board member of RPG, said: “GVK Biosciences expands upon the ResearchPoint Global objective of providing Sponsors with the ability to conduct international studies, knowing that they have best-in-class teams who have successfully executed studies in their local market, fulfilling our promise to provide global capabilities with local expertise.”

Manni Kantipudi, president of GVK Biosciences, said: “We are pleased to be part of ResearchPoint Global. This partnership enables GVK to participate in global trials while focusing on local investigators/recruitment and leveraging lower local costs. While both ResearchPoint Global and GVK are full service CROs offering services independently, together, we hope to offer faster patient recruitment and access to our complete suite of functional services including clinical data management, medical writing, and biostatistics.”